Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vella, A.
Right arrow Articles by Rizza, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vella, A.
Right arrow Articles by Rizza, R. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 49, Issue 4 611-617, Copyright © 2000 by American Diabetes Association

ARTICLES

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

A Vella, P Shah, R Basu, A Basu, JJ Holst and RA Rizza
Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

Although it is well established that glucagon-like peptide 1(7-36) amide (GLP-1) is a potent stimulator of insulin secretion, its effects on insulin action and glucose effectiveness are less clear. To determine whether GLP-1 increases insulin action and glucose effectiveness, subjects with type 2 diabetes were studied on two occasions. Insulin was infused during the night on both occasions to ensure that baseline glucose concentrations were comparable. On the morning of study, either GLP-1 (1.2 pmol x kg(-1) x min(-1)) or saline were infused along with somatostatin and replacement amounts of glucagon. Glucose also was infused in a pattern mimicking that typically observed after a carbohydrate meal. Insulin concentrations were either kept constant at basal levels (n = 6) or varied so as to create a prandial insulin profile (n = 6). The increase in glucose concentration was virtually identical on the GLP-1 and saline study days during both the basal (1.21 +/- 0.15 vs. 1.32 +/- 0.19 mol/l per 6 h) and prandial (0.56 +/- 0.14 vs. 0.56 +/- 0.10 mol/l per 6 h) insulin infusions. During both the basal and prandial insulin infusions, glucose disappearance promptly increased after initiation of the glucose infusion to rates that did not differ on the GLP-1 and saline study days. Suppression of endogenous glucose production also was comparable on the GLP-1 and saline study days during both the basal (-2.7 +/- 0.3 vs. -3.1 +/- 0.2 micromol/kg) and prandial (-3.1 +/- 0.4 vs. -3.0 +/- 0.6 pmol/kg) insulin infusions. We conclude that when insulin and glucagon concentrations are matched, GLP-1 has negligible effects on either insulin action or glucose effectiveness in people with type 2 diabetes. These data strongly support the concept that GLP-1 improves glycemic control in people with type 2 diabetes by increasing insulin secretion, by inhibiting glucagon secretion, and by delaying gastric emptying rather than by altering extrapancreatic glucose metabolism.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev, October 1, 2007; 87(4): 1409 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Basu, R. Singh, A. Basu, C.M. Johnson, and R. A. Rizza
Effect of Nutrient Ingestion on Total-Body and Splanchnic Cortisol Production in Humans
Diabetes, March 1, 2006; 55(3): 667 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Dardevet, M. C. Moore, C. A. DiCostanzo, B. Farmer, D. W. Neal, W. Snead, M. Lautz, and A. D. Cherrington
Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors
Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G806 - G814.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. L. Baggio, Q. Huang, T. J. Brown, and D. J. Drucker
A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis
Diabetes, September 1, 2004; 53(9): 2492 - 2500.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. Dardevet, M. C. Moore, D. Neal, C. A. DiCostanzo, W. Snead, and A. D. Cherrington
Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E75 - E81.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. A. D'Alessio and T. P. Vahl
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. J. Drucker
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Diabetes Care, October 1, 2003; 26(10): 2929 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. L. Prigeon, S. Quddusi, B. Paty, and D. A. D'Alessio
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E701 - E707.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, and A. D. Cherrington
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1027 - E1036.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, M. R.W. Ehlers, J. M. Egan, and D. Elahi
Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes
Diabetes Care, March 1, 2003; 26(3): 837 - 842.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. M. Egan, G. S. Meneilly, J. F. Habener, and D. Elahi
Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3768 - 3773.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Delgado-Aros, D.-Y. Kim, D. D. Burton, G. M. Thomforde, D. Stephens, B. H. Brinkmann, A. Vella, and M. Camilleri
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans
Am J Physiol Gastrointest Liver Physiol, March 1, 2002; 282(3): G424 - G431.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, and D. Elahi
Glucagon-like Peptide-1 (7-37) Augments Insulin-Mediated Glucose Uptake in Elderly Patients With Diabetes
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2001; 56(11): M681 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. S. Meneilly, C. H.S. McIntosh, R. A. Pederson, J. F. Habener, R. Gingerich, J. M. Egan, D. T. Finegood, and D. Elahi
Effect of Glucagon-Like Peptide 1 on Non-Insulin-Mediated Glucose Uptake in the Elderly Patient With Diabetes
Diabetes Care, November 1, 2001; 24(11): 1951 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Vella, P. Shah, R. Basu, A. Basu, M. Camilleri, F. W. Schwenk, J. J. Holst, and R. A. Rizza
Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes
Diabetes, March 1, 2001; 50(3): 565 - 572.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. J. Drucker
Minireview: The Glucagon-Like Peptides
Endocrinology, February 1, 2001; 142(2): 521 - 527.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.